KAUST researchers have developed a CRISPR-Cas system using a heat-stable Cas13 protein (TccCas13a) from Thermoclostridium caenicola, compatible with RT-LAMP for rapid viral detection. The new assay, named OPTIMA-dx, enhances the specificity of RT-LAMP tests by reducing false positives in SARS-CoV-2 detection. The team, led by Dr. Magdy Mahfouz and doctoral student Ahmed Mahas, is transitioning the product to a startup phase for commercialization. Why it matters: This innovation could significantly improve point-of-care diagnostics for COVID-19 and other infections by providing a more accurate and easier-to-use testing method.
A KAUST-led team developed NIRVANA, a portable, briefcase-sized device for rapid detection and sequencing of SARS-CoV-2, influenza, and other viruses. The test utilizes isothermal recombinase amplification (RPA) and was validated on clinical samples and wastewater. NIRVANA can differentiate SARS-CoV-2 strains and doesn't require expensive infrastructure. Why it matters: This innovation enables rapid, decentralized virus detection and surveillance, crucial for pandemic response and monitoring new variants across the region.
KAUST's Bioscience Core Lab (BCL) supports regional and global health initiatives through industry partnerships, offering expertise and technology access to organizations like SaudiVax. BCL aids SaudiVax in developing vaccines and monoclonal antibodies tailored to the needs of Saudi Arabia and the MENA region, focusing on respiratory diseases like MERS and COVID-19. SaudiVax is also collaborating with KAUST to research a new preventative drug targeting SARS-CoV-2. Why it matters: This strengthens Saudi Arabia's capabilities in vaccine development and biomanufacturing, addressing critical healthcare needs in the region and reducing reliance on external sources.
KAUST startup Wayakit has partnered with Swissport International AG to provide its disinfecting products at Jeddah, Dammam, and Riyadh airports. Wayakit's antiviral formulation eliminates 99.999% of bacteria, viruses, and the SARS-CoV-2 strain in 30 seconds. Swissport will use Wayakit to disinfect aircraft and buses, helping to curb the spread of COVID-19 and restore passenger confidence. Why it matters: This partnership highlights the growth of the Saudi startup ecosystem and KAUST's role in fostering innovation and supporting local entrepreneurs in developing advanced biotechnological solutions for critical challenges.
KAUST researchers are developing iSCAN, a rapid, field-deployable COVID-19 test using RT-LAMP coupled with CRISPR-Cas12. The iSCAN system is designed for rapid, specific detection of SARS-CoV-2 and can be deployed by untrained personnel. The researchers are benchmarking iSCAN against commercial kits and seeking emergency use authorization from the Saudi FDA. Why it matters: A rapid, accurate, and field-deployable COVID-19 test could significantly improve pandemic management and control in Saudi Arabia and beyond.
The KAUST Pathogen Genomics Laboratory (PGL), led by Professor Arnab Pain, is using DNA and RNA sequencing to study the SARS-CoV-2 virus. The lab is part of KAUST's Rapid Research Response Team (R3T), supporting Saudi healthcare stakeholders in combating COVID-19. Pain and his Ph.D. student Sharif Hala are partnering with the Saudi-CDC and Ministry of Health hospitals to sequence Saudi SARS-CoV-2 samples. Why it matters: This effort provides crucial data for understanding and monitoring the virus's spread and evolution within the Kingdom, informing public health strategies.
KAUST professor David Ketcheson uses mathematical modeling to understand COVID-19 transmission. He applies differential equations to explain the progression of SARS-CoV-2, utilizing the SIR model to predict the spread. Ketcheson's analysis suggests that the reproduction number for COVID-19 could be as high as 5, emphasizing the need for social distancing. Why it matters: This highlights the role of mathematical modeling and data analysis in understanding and predicting the spread of infectious diseases, particularly in the context of pandemic response.
KAUST researchers are analyzing the SARS-CoV-2 genome to identify potential targets for treatment and vaccine development. They are using the KAUST Metagenome Analysis Platform (KMAP) and the university's supercomputer to compare and analyze genomic data. The research focuses on identifying key genes for detection and treatment of COVID-19. Why it matters: This research contributes to the global effort to combat the pandemic and highlights KAUST's capabilities in genomic data analysis and computational bioscience.